5550 Federal Register / Vol. 89, No. 19 / Monday, January 29, 2024 / Notices 

were realigned to their respective 

divisions. 

The OPQ retitled four of its suboffices 

and retitled the majority of its divisions. 

The OPQ will establish the Office of 

Quality Assurance and within it 

established the Quality Assurance Staff, 

Learning and Professional Staff, and the 

Project Management Staff. 

FDA, CDER, OPQ has been 

restructured as follows: 

DCDL. ORGANIZATION. The Office 

of Pharmaceutical Quality is headed by 

the Director of Pharmaceutical Quality 

and includes the following 

organizational units: 

Office of Pharmaceutical Quality 

(DCDL) 

Office of Product Quality Assessment I 

(DCDLH) 

Division of Product Quality 

Assessment I (DCDLHA) 

Division of Product Quality 

Assessment II (DCDLHB) 

Division of Product Quality 

Assessment III (DCDLHC) 

Division of Product Quality 

Assessment IV (DCDLHD) 

Division of Product Quality 

Assessment V (DCDLHE) 

Division of Product Quality 

Assessment VI (DCDLHF) 

Office of Product Quality Assessment II 

(DCDLB) 

Division of Product Quality 

Assessment VII (DCDLBA) 

Division of Product Quality 

Assessment VIII (DCDLBB) 

Division of Product Quality 

Assessment IX (DCDLBC) 

Division of Product Quality 

Assessment X (DCDLBD) 

Division of Product Quality 

Assessment XI (DCDLBE) 

Division of Product Quality 

Assessment XII (DCDLBF) 

Office of Product Quality Assessment III 

(DCDLA) 

Division of Product Quality 

Assessment XIII (DCDLAA) 

Division of Product Quality 

Assessment XIV (DCDLAB) 

Division of Product Quality 

Assessment XV (DCDLAC) 

Division of Product Quality 

Assessment XVI (DCDLAD) 

Division of Product Quality 

Assessment XVII (DCDLAE) 

Division of Product Quality 

Assessment XVIII (DCDLAF) 

Division of Product Quality 

Assessment XIX (DCDLAG) 

Office of Pharmaceutical Manufacturing 

Assessment (DCDLD) 

Division of Pharmaceutical 

Manufacturing Assessment I 

(DCDLDA) 

Division of Pharmaceutical 

Manufacturing Assessment II 

(DCDLDB) 

Division of Pharmaceutical 

Manufacturing Assessment III 

(DCDLDC) 

Division of Pharmaceutical 

Manufacturing Assessment IV 

(DCDLDD) 

Division of Pharmaceutical 

Manufacturing Assessment V 

(DCDLDE) 

Division of Pharmaceutical 

Manufacturing Assessment VI 

(DCDLDF) 

Office of Program and Regulatory 

Operations (DCDLG) 

Division of Regulatory & Business 

Process Management I (DCDLGA) 

Division of Regulatory & Business 

Process Management II (DCDLGB) 

Division of Regulatory & Business 

Process Management III (DCDLGC) 

Division of Regulatory & Business 

Process Management IV (DCDLGD) 

Office of Pharmaceutical Quality 

Research (DCDLF) 

Division of Pharmaceutical Quality 

Research I (DCDLFA) 

Division of Pharmaceutical Quality 

Research II (DCDLFB) 

Division of Pharmaceutical Quality 

Research III (DCDLFC) 

Division of Pharmaceutical Quality 

Research IV (DCDLFD) 

Division of Pharmaceutical Quality 

Research V (DCDLFE) 

Division of Pharmaceutical Quality 

Research VI (DCDLFF) 

Office of Policy for Pharmaceutical 

Quality (DCDLC) 

Compendial Operations and 

Standards Staff (DCDLCA) 

Division of Regulations and Guidance 

(DCDLCB) 

Division of Internal Policy and 

Communication (DCDLCC) 

Division of Editorial and Project 

Management (DCDLCD) 

Office of Quality Assurance (DCDLJ) 

Quality Assurance Staff (DCDLJ1) 

Learning and Professional 

Development Staff (DCDLJ2) 

Enterprise Project Management Staff 

(DCDLJ3) 

Office of Quality Surveillance (DCDLE) 

Division of Quality Intelligence I 

(DCDLEB) 

Division of Quality Intelligence II 

(DCDLEC) 

Division of Quality Intelligence III 

(DCDLED) 

Office of Administrative Operations 

(DCDLI) 

Administrative Analysis Staff 

(DCDLI1) 

Administrative Operations Staff 1 

(DCDLI2) 

Administrative Operations Staff 2 

(DCDLI3) 

Administrative Operations Staff 3 

(DCDLI4) 

Administrative Operations Staff 4 

(DCDLI5) 

Financial Services Staff (DCDLI6) 

II. Delegations of Authority 

Pending further delegation, directives, 

or orders by the Commissioner of Food 

and Drugs, all delegations and 

redelegations of authority made to 

officials and employees of affected 

organizational components will 

continue in them or their successors 

pending further redelegations, provided 

they are consistent with this 

reorganization. 

III. Electronic Access 

This reorganization is reflected in 

FDA’s Staff Manual Guide (SMG). 

Persons interested in seeing the 

complete SMG can find it on FDA’s 

website at: http://www.fda.gov/ 

AboutFDA/ReportsManualsForms/ 

StaffManualGuides/default.htm. 

(Authority: 44 U.S.C. 3101). 

Xavier Becerra, 

Secretary of Health and Human Services. 

[FR Doc. 2024–01613 Filed 1–26–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request 

Collection of Grants and Contracts 

Data the Historically Black Colleges and 

Universities (HBCUs) and Small 

Businesses May Be Interested in 

Pursuing (Office of the Director) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institutes of Health (NIH), 

Office of the Director, Office of 

Acquisitions and Logistics Management 

(OALM), Small Business Program Office 

(SBPO), has submitted to the Office of 

Management and Budget (OMB) a 

request for review and approval of the 

information collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30-days of the date of this 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 19 / Monday, January 29, 2024 / Notices 5551 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: Keondra Watts, 

Program Analyst, NIH, Office of the 

Director, Office of Acquisitions and 

Logistics Management, Small Business 

Program Office, 6701 Rockledge Dr., 

Bethesda, MD 20892–7786, or call nontoll-free number (301) 443–8722 or 

Email your request, including your 

address to: Keondra.Watts@nih.gov. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on October 27, 2023, pages 

73864–73865 (88 FR 73864) and 

allowed 60 days for public comment. No 

public comments were received. The 

purpose of this notice is to allow an 

additional 30 days for public comment. 

The National Institutes of Health 

(NIH), Office of the Director, Office of 

Acquisitions and Logistics Management, 

Small Business Program Office, may not 

conduct or sponsor, and the respondent 

is not required to respond to any 

information collection that has been 

extended, revised, or implemented on or 

after January 31, 2024, unless it displays 

a currently valid Office of Management 

and Budget (OMB) control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, NIH has 

submitted to OMB a request for review 

and approval of the information 

collection listed below. 

Proposed Collection: Collection of 

Grants and Contracts data the 

Historically Black Colleges and 

Universities (HBCUs) and small 

businesses may be interested in 

pursuing, 0925–0767, exp., date, 01/31/ 

2024, Office of the Director, Office of 

Acquisitions and Logistics Management, 

Small Business Program Office, National 

Institutes of Health. 

Need and Use of Information 

Collection: Presidential Executive Order 

13779 is the White House Initiative to 

Promote Excellence and Innovation 

(PEI) of HBCUs. This Executive Order 

mandates agencies to assist in 

strengthening HBCUs’ ability for 

equitable participation in federal 

programs and explore new ways to 

improve the relationship between the 

federal government and HBCUs. This 

initiative will establish how each 

agency intends to increase the capacity 

of HBCUs to compete effectively for 

grants and contracts. 

The PEI is a comprehensive plan to 

increase the capacity of HBCUs as they 

pursue funding opportunities at the 

NIH. The PEI provides a platform to 

increase transparency between HBCUs 

and the NIH by promoting outreach 

events and training opportunities and 

providing technical assistance. 

Currently, there are six HBCU 

participants and each selected a 

minimum of one small business teaming 

partner to pursue NIH funding 

opportunities with. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

883. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hour 

HBCU Pre-Solicitation Portal for Contracts and 

Grants (Attachment Number 1).

Private Sector ............... 62 18 45/60 837 

Application for Small Business (Attachment Number 5).Private Sector ............... 43 1 45/60 32 

Application for Universities (Attachment Number 

4).

Private Sector ............... 19 1 45/60 14 

Total ............................................................... ....................................... 62 1178 ........................ 883 

Dated: January 23, 2024. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2024–01698 Filed 1–26–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2024–0002] 

Final Flood Hazard Determinations 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: Flood hazard determinations, 

which may include additions or 

modifications of Base Flood Elevations 

(BFEs), base flood depths, Special Flood 

Hazard Area (SFHA) boundaries or zone 

designations, or regulatory floodways on 

the Flood Insurance Rate Maps (FIRMs) 

and where applicable, in the supporting 

Flood Insurance Study (FIS) reports 

have been made final for the 

communities listed in the table below. 

The FIRM and FIS report are the basis 

of the floodplain management measures 

that a community is required either to 

adopt or to show evidence of having in 

effect in order to qualify or remain 

qualified for participation in the Federal 

Emergency Management Agency’s 

(FEMA’s) National Flood Insurance 

Program (NFIP). 

DATES: The date of June 6, 2024 has 

been established for the FIRM and, 

where applicable, the supporting FIS 

report showing the new or modified 

flood hazard information for each 

community. 

ADDRESSES: The FIRM, and if 

applicable, the FIS report containing the 

final flood hazard information for each 

community is available for inspection at 

the respective Community Map 

Repository address listed in the tables 

below and will be available online 

through the FEMA Map Service Center 

at https://msc.fema.gov by the date 

indicated above. 

FOR FURTHER INFORMATION CONTACT: Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 


ddrumheller on DSK120RN23PROD with NOTICES1